EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 849 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Παρακολούθηση και Φροντίδα January 14, 2019 FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma November 13, 2024 Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... December 2, 2024 How Does CAR T-Cell Therapy Work in Treating Cancer? June 17, 2021 Load more HOT NEWS Determination of the Incidence of Driver Mutations in Patients with NSCLC... Cancer in My Community: Reducing Tobacco Use in Tunisia FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma A 27-Year-Old Woman Passed Away. The Note She Wrote The Day...
